Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

By Schlaeppi J-M.  

Cancer and Metastasis Reviews, Vol. 18, Iss. 4, 1999-12 ,pp. : 473-481

Springer Publishing Company

Access to resources Recommend Favorite

Mechanism of action of anti-HER2 monoclonal antibodies

By Baselga J.   Albanell J.  

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 35-41

Springer Publishing Company

Access to resources Recommend Favorite

Effects of a Lytic Peptide Conjugated to hCG on Ovarian Cancer: Studies in Vitro and in Vivo

By Gawronska B.   Leuschner C.   Enright F.M.   Hansel W.  

Gynecologic Oncology, Vol. 85, Iss. 1, 2002-04 ,pp. : 45-52

Elsevier

Access to resources Recommend Favorite

In vivo and in situ imaging of head and neck squamous cell carcinoma using near-infrared fluorescent quantum dot probes conjugated with epidermal growth factor receptor monoclonal antibodies in mice

By                  

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 1925-1931

Spandidos Publications

Access to resources Recommend Favorite

Anti-idiotypic Response to Antigrowth Factor Receptor Monoclonal Antibodies

By Tosi E.   Valota O.   Canevari S.   Adobati E.   Casalini P.   Perez P.   Colnaghi M.I.  

European Journal of Cancer, Vol. 32, Iss. 3, 1996-03 ,pp. : 498-505

Elsevier

Access to resources Recommend Favorite